Selected article for: "cell surface and viral release"

Author: Ejaz, Hasan; Alsrhani, Abdullah; Zafar, Aizza; Javed, Humera; Junaid, Kashaf; Abdalla, Abualgasim E.; Abosalif, Khalid O.A.; Ahmed, Zeeshan; Younas, Sonia
Title: COVID-19 and comorbidities: Deleterious impact on infected patients
  • Cord-id: 19qx02x4
  • Document date: 2020_8_4
  • ID: 19qx02x4
    Snippet: The pandemic situation with the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from China has endangered human lives. Coronavirus disease 2019 (COVID-19) is presented with asymptomatic, mild, or severe pneumonia-like symptoms. COVID-19 patients with diabetes, chronic obstructive pulmonary disease (COPD), cardiovascular diseases (CVD), hypertension, malignancies, HIV, and other comorbidities could develop a life-threatening situation. SARS-CoV-2 utilizes ACE-2 receptors
    Document: The pandemic situation with the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from China has endangered human lives. Coronavirus disease 2019 (COVID-19) is presented with asymptomatic, mild, or severe pneumonia-like symptoms. COVID-19 patients with diabetes, chronic obstructive pulmonary disease (COPD), cardiovascular diseases (CVD), hypertension, malignancies, HIV, and other comorbidities could develop a life-threatening situation. SARS-CoV-2 utilizes ACE-2 receptors found at the surface of the host cells to get inside the cell. Certain comorbidities are associated with a strong ACE-2 receptor expression and higher release of proprotein convertase that enhance the viral entry into the host cells. The comorbidities lead to the COVID-19 patient into a vicious infectious circle of life and are substantially associated with significant morbidity and mortality. The comorbid individuals must adopt the vigilant preventive measure and requires scrupulous management. In this review, we rigorously focused on the impact of common morbidities in COVID-19 patients and recapitulated the management strategies with recent directions. We found limited resources describing the association of comorbidities in COVID-19; however, our review delineates the broader spectrum of comorbidities with COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • administration rate and liver kidney: 1
    • administration rate and liver kidney heart: 1
    • administration rate and liver kidney heart lung: 1
    • admission rate and liver damage: 1, 2, 3, 4, 5
    • admission rate and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • admission rate and liver injury: 1, 2, 3, 4, 5
    • admission rate and liver kidney: 1, 2, 3, 4
    • admission rate and lung inflammation: 1
    • admission rate and lung injury: 1, 2, 3, 4
    • admission requirement and liver disease: 1, 2, 3, 4, 5, 6, 7, 8
    • admission requirement and liver enzyme: 1
    • admission requirement and liver injury: 1, 2, 3, 4
    • admission requirement and liver kidney: 1, 2, 3, 4
    • liver cell and lung carcinoma: 1, 2, 3, 4
    • liver cell and lung inflammation: 1
    • liver cell and lung injury: 1, 2, 3, 4, 5, 6
    • liver damage and lung inflammation: 1
    • liver damage and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • low grade inflammation and lung inflammation: 1, 2, 3, 4, 5